Ueno H, Kiyosawa K, Kaniwa N
Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Br J Cancer. 2007 Jul 16;97(2):145-51. doi: 10.1038/sj.bjc.6603860. Epub 2007 Jun 26.
Gemcitabine is a deoxycytidine analogue that has a broad spectrum of antitumour activity in many solid tumours including pancreatic cancer. We have recently carried out a pharmacogenomic study in cancer patients treated with gemcitabine, and found that one genetic polymorphism of an enzyme involved in gemcitabine metabolism can cause interindividual variations in the pharmacokinetics and toxicity of this agent. In this paper, we review recent genetic studies of gemcitabine, and discuss the possibility of individualised cancer chemotherapy based on a pharmacogenomic approach.
吉西他滨是一种脱氧胞苷类似物，在包括胰腺癌在内的许多实体瘤中具有广泛的抗肿瘤活性。我们最近对接受吉西他滨治疗的癌症患者进行了一项药物基因组学研究，发现参与吉西他滨代谢的一种酶的基因多态性可导致该药物的药代动力学和毒性存在个体间差异。在本文中，我们综述了吉西他滨的近期基因研究，并讨论了基于药物基因组学方法进行个体化癌症化疗的可能性。
